CANN6; CB-R; CNR1; CB1A; CB1K5; CB1R; CNR
Human CB1 full length protein membrane nanoparticles (MNPs)
Neuroactive ligand-receptor interaction
The human full length CB1 Protein has a MW of 52.7 kDa
|Formulation & Reconstitution||
Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
|Storage & Shipping||
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
The cannabinoids, principally delta-9-tetrahydrocannabinol and synthetic analogs, are psychoactive ingredients of marijuana. The cannabinoid receptors are members of the guanine-nucleotide-binding protein (G-protein) coupled receptor family, which inhibit adenylate cyclase activity in a dose-dependent, stereoselective and pertussis toxin-sensitive manner. The two receptors have been found to be involved in the cannabinoid-induced CNS effects (including alterations in mood and cognition) experienced by users of marijuana. Multiple transcript variants encoding two different protein isoforms have been described for this gene.
Research use only
Human CB1 full length protein-MNP
Price: 50 μg $1200.00 ; 100 μg $1600.00
Figure1. Elisa plates were pre-coated with 0.5μg/per well purified human CB1 full length membrane nanoparticles. Serial diluted anti-CB1 monoclonal antibody (DME100144) solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-CB1 monoclonal antibody binding with CB1 full length membrane nanoparticles is 439.6ng/ml.
Figure2. FACS analysis of CB1 MNPs
A. Negative Control 1: CB1 full length membrane nanoparticles samples were stained only with Goat anti-human lgG 488 secondary antibody.
B. Negative Control 2: Control membrane nanoparticles samples were stained with anti-CB1 antibody (BME100049) at 2μg/mL, followed by Goat anti-human IgG 488 secondary antibody.
C. Negative Control 3: CB1 full length membrane nanoparticles samples were stained with anti-CCR8 antibody (an irrelevant antibody) at 2μg/mL, followed by Goat anti-human IgG 488 secondary antibody.
D. CB1 full length membrane nanoparticles samples were stained with anti-CB1 antibody (BME100049) at 2μg/mL, followed by Goat anti-human IgG 488 secondary antibody.